CD276 and pancreatic neoplasm: In 29 of 137 (21%) pancreatic cancer patients we observed weak (17.5%) to intermediate (3.7%) B7-H3 expression in cancer cells, whereas in 63% of these patients weak (46%) to intermediate (17%) B7-H3 expression in tumor stroma was found.